Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
Lansky AJ, Yaqub M, Hermiller JB, Smith RS, Farhat N, Caputo R, Williams JE, Sanz M, Koo K, Sood P, Sudhir K, Stone GW. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention 2010, 6 Suppl J: j44-52. PMID: 21930490, DOI: 10.4244/eijv6supja8.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelProspective StudiesProsthesis DesignRisk AssessmentRisk FactorsSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeUnited StatesConceptsPeriprocedural myocardial infarctionSide branch occlusionBranch occlusionMyocardial infarctionStent placementDrug-eluting stent placementIndependent angiographic core laboratoryPaclitaxel-eluting stent placementLong-term adverse outcomesSPIRIT III trialPaclitaxel-eluting stentsAngiographic core laboratoryThree-year resultsLower ratesSide branchesEES armIII trialsMI ratesIndependent predictorsClinical outcomesAdverse outcomesProcedural angiogramsGrade 0Stent typeCore laboratory